We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookies
Accept
Read more
Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Our products
& pipeline
Diseases we target
GS010 for LHON
GS030 for Retinitis Pigmentosa
GS030 for Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Investors
& media
Company Overview
Press releases
Events & presentations
News and press coverage
Stock information
Governance
Documentation
GS010 - LUMEVOQ
Year
All
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
24 Jun 2021 - 25 Jun 2021
UMDF Mitochondrial Medicine 2021 – virtual
15 Jun 2021
Clinical Operations Strategy Meeting online 2021
14 Jun 2021 - 18 Jun 2021
BIO US 2021 – Digital
01 June 2021
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
19 May 2021 - 21 May 2021
Advanced Therapies – Virtual
14 May 2021
GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19
03 May 2021
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
01 May 2021 - 07 May 2021
2021 ARVO Annual Meeting, virtual
22 Mar 2021 - 25 Mar 2021
BioEurope Spring – virtual
17 Apr 2021 - 22 Apr 2021
2021 AAN Annual Meeting, virtual
1
2
3
4
5
6
…
10
View next 9 articles
Go back to the page of the page
